BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li GH, Qu Q, Qi TT, Teng XQ, Zhu HH, Wang JJ, Lu Q, Qu J. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance. J Exp Clin Cancer Res 2021;40:174. [PMID: 34011395 DOI: 10.1186/s13046-021-01974-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Walker RR, Rentia Z, Chiappinelli KB. Epigenetically programmed resistance to chemo- and immuno-therapies. Advances in Cancer Research 2023. [DOI: 10.1016/bs.acr.2022.12.001] [Reference Citation Analysis]
2 Kang Y, Ji Z, Li H, Tsao H. Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping. J Invest Dermatol 2022:S0022-202X(22)02830-5. [PMID: 36529262 DOI: 10.1016/j.jid.2022.03.039] [Reference Citation Analysis]
3 Li H, Muhetaer G, Xie Y, Yao K, Ma Q, Guan H, Xing S, Huang X, Zhou J. Identification of super-enhancer-driven peptidyl arginine deiminases as potential biomarkers and therapeutic targets for osimertinib-resistant non-small cell lung cancer. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1071365] [Reference Citation Analysis]
4 Koutsi MA, Pouliou M, Champezou L, Vatsellas G, Giannopoulou A, Piperi C, Agelopoulos M. Typical Enhancers, Super-Enhancers, and Cancers. Cancers 2022;14:4375. [DOI: 10.3390/cancers14184375] [Reference Citation Analysis]
5 Saito T, Asai S, Tanaka N, Nohata N, Minemura C, Koma A, Kikkawa N, Kasamatsu A, Hanazawa T, Uzawa K, Seki N. Genome-Wide Super-Enhancer-Based Analysis: Identification of Prognostic Genes in Oral Squamous Cell Carcinoma. IJMS 2022;23:9154. [DOI: 10.3390/ijms23169154] [Reference Citation Analysis]
6 Zhu H, Chen K, Chen Y, Liu J, Zhang X, Zhou Y, Liu Q, Wang B, Chen T, Cao X. RNA-binding protein ZCCHC4 promotes human cancer chemoresistance by disrupting DNA-damage-induced apoptosis. Signal Transduct Target Ther 2022;7:240. [PMID: 35853866 DOI: 10.1038/s41392-022-01033-8] [Reference Citation Analysis]
7 Kim HJ, Moon SJ, Hong S, Won HH, Kim JH. DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300. Nucleic Acids Res 2022:gkac585. [PMID: 35801925 DOI: 10.1093/nar/gkac585] [Reference Citation Analysis]
8 Napoli S, Munz N, Guidetti F, Bertoni F. Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades. Cancers 2022;14:1978. [DOI: 10.3390/cancers14081978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Ding L, Li L, Tang Z. Cisplatin resistance and malignant behaviors of lung cancer cells are promoted by circ_0002360 via targeting miR-6751-3p to regulate the expression of ZNF300. Thorac Cancer 2022. [PMID: 35166026 DOI: 10.1111/1759-7714.14342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mini E, Landini I, Di Paolo A, Ravegnini G, Saponara S, Frosini M, Lapucci A, Nobili S. Predictive “omic” biomarkers of drug response: Colorectal cancer as a model. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy 2022. [DOI: 10.1016/b978-0-323-90190-1.00002-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer 2021;20. [DOI: 10.1186/s12943-021-01464-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
12 Li M, Yang B, Li X, Ren H, Zhang L, Li L, Li W, Wang X, Zhou H, Zhang W. Identification of Prognostic Factors Related to Super Enhancer-Regulated ceRNA Network in Metastatic Lung Adenocarcinoma. Int J Gen Med 2021;14:6261-75. [PMID: 34629892 DOI: 10.2147/IJGM.S332317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lemaire V, Shemesh CS, Rotte A. Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. J Exp Clin Cancer Res 2021;40:311. [PMID: 34598713 DOI: 10.1186/s13046-021-02111-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]